Aaron Task told a caller to Jim Cramer's
"RealMoney" radio show Wednesday that
, is the kind of stock that might perform well once we get past Thursday's
Task, co-executive editor of
, is filling in for Cramer this week.
The company has good growth prospects and international expansion, but if it falls below $33 (it was recently at $35.72),Task said he would be worried.
For now, however, Task believes that the caller is in good shape.
Energy Conversion Devices
looks like it's in bad shape, as the froth has come out of alternative energy plays as of late, Task said. He added that he would be wary of owning it in this environment.
When a caller inquired about
, Task said it was a darling, but has slipped a bit in recent weeks.
Task said that Genentech is a stock where huge expectations have been built up and that's one of its problems.
Guest Noah Blackstein, the lead portfolio manager for the
Dynamic Power American Growth Fund
and frequent guest on "CNBC's" other outlets, called Genentech one of the fastest-growing biotech companies in the next five years.
It shot up from $20 to $100 in a year and a half (it was recently at $77.92) and the company is digesting the big move, Blackstein said.
If we are going into a slower growth period, then Genentech will be sought out for its growth, Blackstein said, adding that he likes the company very much.
Task said that
, which Cramer owns for his charitable trust,
Action Alerts PLUS, is poised to benefit here if the Fed doesn't kill the economy.
Blackstein said that overall, it is difficult to look at stock today and determine why it's going down, as Citrix has been. He said the fundamentals of the company have remained strong.
To see the most recent edition of The RealMoney Radio Recap in its entirety, please click here. This recap is published every day around 3 p.m. ET.
Aaron L. Task is the co-executive editor of TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships.
to send him an email.